Vicki Sokolik refuses to be an Ostrich. Her son brought to her attention the crisis of unhoused youth — youth unhoused, not living with a parent/guardian, and not in foster care — in America, and she has been fighting to support this vulnerable population every since. Most active in Tampa Bay, Florida, Vicki is the founder and CEO of the nonprofit Starting Right, Now, which removes barriers for unaccompanied homeless youth to cultivate long-term well-being and self-sufficiency. She is also the author of the new book, “If You See Them: Young, Unhoused, and Alone in America.” Vicki Sokolik joined host Jay Ruderman to discuss the many ways unhoused youth fall through the cracks in our society, how her organization helps them, and also how to build trust with people who could use your help. Episode Chapters (00:00) Intro (01:10) Vicki’s origin story (02:40) What is “unhoused youth?” (06:40) What should a person do if they worry they see an unhoused youth? (08:19) How have conversations around unhoused youth changed in Vicki’s 20 years working with them? (11:02) How do people get the word out and help unhoused youth? (14:55) Vicki’s new book (16:48) How Vicki builds trust (20:10) What do students receive at Starting Right, Now? (22:58) How does Vicki balance advocacy and direct support? (27:53) Starting Right, Now alumni (29:10) Goodbye For video episodes, watch on www.youtube.com/@therudermanfamilyfoundation Stay in touch: X: @JayRuderman | @RudermanFdn LinkedIn: Jay Ruderman | Ruderman Family Foundation Instagram: All About Change Podcast | Ruderman Family Foundation To learn more about the podcast, visit https://allaboutchangepodcast.com/…
MediCom Oncology Clinical Pearl Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting, in under three minutes. Leading experts and academic faculty from top research and practice institutions provide guidance to community-based healthcare providers, including oncologists, pharmacists and nurses. Podcasts are brought to you by MediCom Worldwide, Inc., an accredited, independent medical education company. Podcasts are intended for licensed adul ...
…
continue reading
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.توسط MediCom Oncology
…
continue reading
Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.توسط MediCom Oncology
…
continue reading
Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.توسط MediCom Oncology
…
continue reading
1
How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance
3:58
In this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).توسط MediCom Oncology
…
continue reading
Listen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.توسط MediCom Oncology
…
continue reading
Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.توسط MediCom Oncology
…
continue reading
Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.توسط MediCom Oncology
…
continue reading
1
What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics?
2:40
Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.توسط MediCom Oncology
…
continue reading
Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.توسط MediCom Oncology
…
continue reading
Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.توسط MediCom Oncology
…
continue reading
1
What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma?
3:01
Listen as Dr. Matasar discusses survivorship care for patients who have been treated for classical Hodgkin lymphoma, including late effects of treatment.توسط MediCom Oncology
…
continue reading
Dr. Jacob Laubach discusses second primary malignancies associated with lenalidomide maintenance in the transplant and post-transplant setting.توسط MediCom Oncology
…
continue reading
Dr. Laubach discusses the impact of consolidation therapy in patients post-transplant, referencing results of the CTN StaMINA trial.توسط MediCom Oncology
…
continue reading
Dr. Jacob Laubach discusses bortezomib as an alternate strategy to lenalidomide for maintenance therapy in patients with multiple myeloma.توسط MediCom Oncology
…
continue reading
Listen as Dr. Matasar discusses the future role of brentuximab vedotin in patients with newly diagnosed classical Hodgkin lymphoma.توسط MediCom Oncology
…
continue reading
Dr. Ruben Niesvizky discusses MRD testing and how it has become a standard of care in multiple myeloma, as well as future directions in MRD testing that will improve outcomes in these patients.توسط MediCom Oncology
…
continue reading
Dr. O'Reilly provides an insightful overview of how the emerging use of precision medicine and the Precision Promise [SM] initiative will impact the new drug approval process in pancreatic cancer.توسط MediCom Oncology
…
continue reading
Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.توسط MediCom Oncology
…
continue reading
1
What are the optimal imaging methods to determine extent of bone disease in newly diagnosed MM?
3:18
Dr. Ruben Niesvizky discusses newer approaches for imaging in patients who have multiple myeloma with bone disease, including the benefits of combining modalities such MRI and PET scan.توسط MediCom Oncology
…
continue reading
1
The standard of care for patients receiving lenalidomide or thalidomide who are at high risk for VTE
3:36
Dr. Ruben Niesvizky discusses clinical approaches to managing the risk of developing VTE in myeloma patients receiving immunomodulating agents such as lenalidomide or thalidomide.توسط MediCom Oncology
…
continue reading
In under two minutes, Dr. Carol Ann Huff will discuss how to dose daratumumab in conjunction with lenalidomide and dexamethasone in patients with multiple myeloma.توسط MediCom Oncology
…
continue reading
Dr. Anil Rustgi discusses a clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes.توسط MediCom Oncology
…
continue reading
Dr. Stuart Goldberg briefly summarizes updates on CPX-351, a liposomal form of cytarabine and daunorubicin that allows for office infusion vs. standard consolidation requiring hospitalization.توسط MediCom Oncology
…
continue reading
Listen as Dr. Huff discusses the infusion duration for carfilzomib in patients with multiple myeloma.توسط MediCom Oncology
…
continue reading
Listen as Dr. O'Reilly discusses the the current status of immunotherapy in pancreatic cancer.توسط MediCom Oncology
…
continue reading
Listen for just under two minutes as Dr. Harvey explains measuring frailty in patients being treated for multiple myeloma.توسط MediCom Oncology
…
continue reading
Dr. Eytan Stein provides a brief update on patients experiencing differentiation syndrome in a larger enasidenib trial, detailing the creation of a Differentiation Syndrome Review Committee.توسط MediCom Oncology
…
continue reading
Listen as Dr. Carol Ann Huff discusses how to dose daratumumab, bortezomib and dexamethasone in the combination regimen.توسط MediCom Oncology
…
continue reading
Listen as Dr. Philip McCarthy provides an update on the CALGB-100104 (Alliance) randomized trial.توسط MediCom Oncology
…
continue reading
1
How does the safety profile of the new and emerging anti-PD 1 antibodies differ from chemotherapy?
1:55
Listen as Dr. Alison Moskowitz discusses the difference between the safety profile of the new and emerging anti-PD-1 antibodies and chemotherapy.توسط MediCom Oncology
…
continue reading
Dr. Sagar Lonial provides a brief update on the ELOQUENT-2 phase 3 trial and how it continues to demonstrate a benefit in terms of progression-free survival.توسط MediCom Oncology
…
continue reading
Listen for just under two minutes as Dr. Harvey discusses optimal pre-medications for daratumumab, including H1 antagonists.توسط MediCom Oncology
…
continue reading
Listen as Dr. Harvey will discuss rash management for patients taking IRd.توسط MediCom Oncology
…
continue reading
Listen as Dr. Niesvizky explains the appropriate management for severe hypercalcemia.توسط MediCom Oncology
…
continue reading
1
What is the most common cause of renal failure in newly diagnosed patients with multiple myeloma?
1:54
Listen as Dr. Niesvizky discusses the most common cause of renal failure in newly diagnosed patients with MM.توسط MediCom Oncology
…
continue reading
Listen as Dr. Wang-Gillam discusses the standard dosing and delivery of Nal-IRI + 5-FU/LV.توسط MediCom Oncology
…
continue reading
1
How important is the availability of supportive care when considering transplant in older patients?
2:26
Listen as Dr. Ritchie discusses the importance of available supportive care when considering transplant in older patients with MDS.توسط MediCom Oncology
…
continue reading
1
Is the AE profile of BV the same or different from traditional monoclonal antibody therapies?
2:09
Listen as Dr. Moskowitz discusses the AE profile of BV and traditional monoclonal antibody therapies.توسط MediCom Oncology
…
continue reading
1
When do you need to do a bone marrow biopsy in the management or assessment of multiple myeloma?
2:37
Listen as Dr. Richter discusses when you need to do a bone marrow biopsy in the management or assessment of multiple myeloma.توسط MediCom Oncology
…
continue reading
Listen as Dr. Moskowitz discusses the more common adverse reactions associated with brentuximab vedotin and how they are most often managed.توسط MediCom Oncology
…
continue reading
Listen as Dr. Richter will discuss the different technologies used to assess cytogenetic risk status in your myeloma patient.توسط MediCom Oncology
…
continue reading
Listen as Dr. Richter will discuss the meaning of high-risk myeloma.توسط MediCom Oncology
…
continue reading
Listen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of FOLFIRNOX in patients with pancreatic cancer.توسط MediCom Oncology
…
continue reading
Listen as Dr. Anas Younes covers the new FDA approval of pembrolizumab for patients with cHL.توسط MediCom Oncology
…
continue reading
Listen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of gemcitabine/nab-paclitaxel in patients with pancreatic cancer.توسط MediCom Oncology
…
continue reading
Listen as Dr. Rami Komrokji explains how to diagnose chronic myelomonocytic leukemia (CMML).توسط MediCom Oncology
…
continue reading
Listen as Dr. Rami Komrokji discusses what tests to obtain upfront at the time of MDS diagnosis.توسط MediCom Oncology
…
continue reading
Listen as Dr. Donald Harvey explains how to manage diarrhea in patients taking ixazomib.توسط MediCom Oncology
…
continue reading
Listen as Dr. Donald Harvey explains which prophylactic antithrombotic agents are safe to use with lenalidomide.توسط MediCom Oncology
…
continue reading